Drug intelligence / Profile preview

xenadrine rfa

Development stage
Discontinued
Lead developer
CytoDyn
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Xenadrine RFA is an over-the-counter dietary supplement that was marketed for weight loss and athletic performance enhancement. Its primary active ingredients were ma huang (a source of ephedra alkaloids) and guarana seed (a source of caffeine). The mechanism of action involves stimulation of the sympathetic nervous system through direct agonism at alpha- and beta-adrenergic receptors by ephedrine alkaloids, leading to increased heart rate, blood pressure, metabolism, appetite suppression, and enhanced fat breakdown. Guarana provides additional stimulant effects via caffeine. The product was associated with serious cardiovascular adverse events including myocardial infarction, stroke, seizures, hypertension, arrhythmias, coronary thrombosis and even death. Due to safety concerns related to its ephedra content—especially heightened risk for cardiovascular complications—the FDA banned the sale of supplements containing ephedra in 2004[1][2][3][6]. Claims regarding its efficacy for weight loss were not substantiated by rigorous clinical evidence[5].

Brand names
Xenadrine RFAXenadrine RFA-1
Other names
ma huang and guarana combination supplementephedra-caffeine weight loss supplement
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADRA1A (α1A)ADORA2A (Adenosine A₂A Receptor)ADRB1 (β1)

Beyond the preview

Go deeper on xenadrine rfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on xenadrine rfa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call